{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:01:58Z","timestamp":1786978918546,"version":"build-2736575974"},"publisher-location":"Cham","reference-count":68,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783031612374","type":"print"},{"value":"9783031612381","type":"electronic"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1007\/978-3-031-61238-1_9","type":"book-chapter","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T02:03:06Z","timestamp":1724983386000},"page":"165-184","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cholangiocarcinoma"],"prefix":"10.1007","author":[{"given":"Matthew E.","family":"Dixon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam G.","family":"Pappas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,31]]},"reference":[{"issue":"1","key":"9_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12253-018-0491-8","volume":"26","author":"G Lendvai","year":"2020","unstructured":"Lendvai G, Szekercz\u00e9s T, Illy\u00e9s I et al (2020) Cholangiocarcinoma: classification, histopathology and molecular carcinogenesis. Pathol Oncol Res 26(1):3\u201315. https:\/\/doi.org\/10.1007\/s12253-018-0491-8","journal-title":"Pathol Oncol Res"},{"issue":"4","key":"9_CR2","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.soc.2019.06.002","volume":"28","author":"R El-Diwany","year":"2019","unstructured":"El-Diwany R, Pawlik TM, Ejaz A (2019) Intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am 28(4):587\u2013599. https:\/\/doi.org\/10.1016\/j.soc.2019.06.002","journal-title":"Surg Oncol Clin N Am"},{"issue":"1","key":"9_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/hep.510310104","volume":"31","author":"KS Suh","year":"2000","unstructured":"Suh KS, Roh HR, Koh YT, Lee KU, Park YH, Kim SW (2000) Clinicopathologic features of the intraductal growth type of peripheral cholangiocarcinoma. Hepatology 31(1):12\u201317. https:\/\/doi.org\/10.1002\/hep.510310104","journal-title":"Hepatology"},{"issue":"12","key":"9_CR4","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.hpb.2018.05.017","volume":"20","author":"F Bagante","year":"2018","unstructured":"Bagante F, Weiss M, Alexandrescu S et al (2018) Long-term outcomes of patients with intraductal growth sub-type of intrahepatic cholangiocarcinoma. HPB 20(12):1189\u20131197. https:\/\/doi.org\/10.1016\/j.hpb.2018.05.017","journal-title":"HPB"},{"issue":"5","key":"9_CR5","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1097\/01.sla.0000251366.62632.d3","volume":"245","author":"ML DeOliveira","year":"2007","unstructured":"DeOliveira ML, Cunningham SC, Cameron JL et al (2007) Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 245(5):755\u2013762. https:\/\/doi.org\/10.1097\/01.sla.0000251366.62632.d3","journal-title":"Ann Surg"},{"issue":"4","key":"9_CR6","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.soc.2019.06.012","volume":"28","author":"AW Hemming","year":"2019","unstructured":"Hemming AW (2019) Biliary tract and primary liver tumors: who, what, and why? Surg Oncol Clin N Am 28(4):519\u2013538. https:\/\/doi.org\/10.1016\/j.soc.2019.06.012","journal-title":"Surg Oncol Clin N Am"},{"issue":"5","key":"9_CR7","doi-asserted-by":"publisher","first-page":"666","DOI":"10.3748\/wjg.14.666","volume":"14","author":"N Kaewpitoon","year":"2008","unstructured":"Kaewpitoon N, Kaewpitoon SJ, Pengsaa P, Sripa B (2008) Opisthorchis viverrini: the carcinogenic human liver fluke. World J Gastroenterol 14(5):666\u2013674. https:\/\/doi.org\/10.3748\/wjg.14.666","journal-title":"World J Gastroenterol"},{"issue":"5","key":"9_CR8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/jhbp.62","volume":"21","author":"P Sithithaworn","year":"2014","unstructured":"Sithithaworn P, Yongvanit P, Duenngai K, Kiatsopit N, Pairojkul C (2014) Roles of liver fluke infection as risk factor for cholangiocarcinoma. J Hepatobiliary Pancreat Sci 21(5):301\u2013308. https:\/\/doi.org\/10.1002\/jhbp.62","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"2","key":"9_CR9","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.bpg.2015.02.003","volume":"29","author":"A Bergquist","year":"2015","unstructured":"Bergquist A, von Seth E (2015) Epidemiology of cholangiocarcinoma. Best Pract Res Clin Gastroenterol 29(2):221\u2013232. https:\/\/doi.org\/10.1016\/j.bpg.2015.02.003","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"9_CR10","doi-asserted-by":"publisher","unstructured":"Alvaro D, Bragazzi MC, Benedetti A et al (2011) Cholangiocarcinoma in Italy: a national survey on clinical characteristics, diagnostic modalities and treatment. Results from the \u201cCholangiocarcinoma\u201d committee of the Italian Association for the Study of Liver disease. Dig Liver Dis 43(1):60\u201365. https:\/\/doi.org\/10.1016\/j.dld.2010.05.002","DOI":"10.1016\/j.dld.2010.05.002"},{"issue":"5","key":"9_CR11","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1053\/ejso.1999.0925","volume":"26","author":"DV Mann","year":"2000","unstructured":"Mann DV, Edwards R, Ho S, Lau WY, Glazer G (2000) Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 26(5):474\u2013479. https:\/\/doi.org\/10.1053\/ejso.1999.0925","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"9_CR12","doi-asserted-by":"publisher","first-page":"332","DOI":"10.4251\/wjgo.v13.i5.332","volume":"13","author":"G Rompianesi","year":"2021","unstructured":"Rompianesi G, Di Martino M, Gordon-Weeks A, Montalti R, Troisi R (2021) Liquid biopsy in cholangiocarcinoma: current status and future perspectives. World J Gastrointest Oncol 13(5):332\u2013350. https:\/\/doi.org\/10.4251\/wjgo.v13.i5.332","journal-title":"World J Gastrointest Oncol"},{"issue":"5","key":"9_CR13","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1148\/rg.285075183","volume":"28","author":"NI Sainani","year":"2008","unstructured":"Sainani NI, Catalano OA, Holalkere NS, Zhu AX, Hahn PF, Sahani DV (2008) Cholangiocarcinoma: current and novel imaging techniques. Radiographics 28(5):1263\u20131287. https:\/\/doi.org\/10.1148\/rg.285075183","journal-title":"Radiographics"},{"issue":"18","key":"9_CR14","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.3748\/wjg.v13.i18.2529","volume":"13","author":"AM Halefoglu","year":"2007","unstructured":"Halefoglu AM (2007) Magnetic resonance cholangiopancreatography: a useful tool in the evaluation of pancreatic and biliary disorders. World J Gastroenterol 13(18):2529\u20132534. https:\/\/doi.org\/10.3748\/wjg.v13.i18.2529","journal-title":"World J Gastroenterol"},{"key":"9_CR15","doi-asserted-by":"publisher","unstructured":"Hekimoglu K, Ustundag Y, Dusak A et al (2008) MRCP vs. ERCP in the evaluation of biliary pathologies: review of current literature. J Dig Dis 9(3):162\u2013169. https:\/\/doi.org\/10.1111\/j.1751-2980.2008.00339.x","DOI":"10.1111\/j.1751-2980.2008.00339.x"},{"issue":"5","key":"9_CR16","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/j.1477-2574.2011.00298.x","volume":"13","author":"JK Heimbach","year":"2011","unstructured":"Heimbach JK, Sanchez W, Rosen CB, Gores GJ (2011) Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination. HPB 13(5):356\u2013360. https:\/\/doi.org\/10.1111\/j.1477-2574.2011.00298.x","journal-title":"HPB"},{"issue":"6","key":"9_CR17","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1177\/0003134820923287","volume":"86","author":"LM Enomoto","year":"2020","unstructured":"Enomoto LM, Dixon MEB, Burdette A, Gusani NJ (2020) Biliary drainage before and after liver resection for perihilar cholangiocarcinoma. Am Surg 86(6):628\u2013634. https:\/\/doi.org\/10.1177\/0003134820923287","journal-title":"Am Surg"},{"issue":"9 Pt 2","key":"9_CR18","first-page":"S243","volume":"14","author":"DR Burke","year":"2003","unstructured":"Burke DR, Lewis CA, Cardella JF et al (2003) Quality improvement guidelines for percutaneous transhepatic cholangiography and biliary drainage. J Vasc Interv Radiol 14(9 Pt 2):S243\u2013S246","journal-title":"J Vasc Interv Radiol"},{"issue":"10","key":"9_CR19","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1111\/j.1365-2036.2007.03289.x","volume":"25","author":"P Jethwa","year":"2007","unstructured":"Jethwa P, Breuning E, Bhati C, Buckles J, Mirza D, Bramhall S (2007) The microbiological impact of pre-operative biliary drainage on patients undergoing hepato-biliary-pancreatic (HPB) surgery. Aliment Pharmacol Ther 25(10):1175\u20131180. https:\/\/doi.org\/10.1111\/j.1365-2036.2007.03289.x","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"9_CR20","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1007\/s00534-011-0404-7","volume":"18","author":"H Kawakami","year":"2011","unstructured":"Kawakami H, Kondo S, Kuwatani M et al (2011) Preoperative biliary drainage for hilar cholangiocarcinoma: which stent should be selected? J Hepatobiliary Pancreat Sci 18(5):630\u2013635. https:\/\/doi.org\/10.1007\/s00534-011-0404-7","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"3","key":"9_CR21","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/s0016-5085(99)70461-0","volume":"117","author":"H Miyoshi","year":"1999","unstructured":"Miyoshi H, Rust C, Roberts PJ, Burgart LJ, Gores GJ (1999) Hepatocyte apoptosis after bile duct ligation in the mouse involves Fas. Gastroenterology 117(3):669\u2013677. https:\/\/doi.org\/10.1016\/s0016-5085(99)70461-0","journal-title":"Gastroenterology"},{"issue":"4","key":"9_CR22","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1053\/gast.2002.35953","volume":"123","author":"A Canbay","year":"2002","unstructured":"Canbay A, Higuchi H, Bronk SF, Taniai M, Sebo TJ, Gores GJ (2002) Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology 123(4):1323\u20131330. https:\/\/doi.org\/10.1053\/gast.2002.35953","journal-title":"Gastroenterology"},{"issue":"4","key":"9_CR23","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/hep.20380","volume":"40","author":"JS Gujral","year":"2004","unstructured":"Gujral JS, Liu J, Farhood A, Jaeschke H (2004) Reduced oncotic necrosis in Fas receptor-deficient C57BL\/6J-lpr mice after bile duct ligation. Hepatology 40(4):998\u20131007. https:\/\/doi.org\/10.1002\/hep.20380","journal-title":"Hepatology"},{"issue":"2","key":"9_CR24","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/SLA.0b013e31826f4b0e","volume":"257","author":"C Iacono","year":"2013","unstructured":"Iacono C, Ruzzenente A, Campagnaro T, Bortolasi L, Valdegamberi A, Guglielmi A (2013) Role of preoperative biliary drainage in jaundiced patients who are candidates for pancreatoduodenectomy or hepatic resection: highlights and drawbacks. Ann Surg 257(2):191\u2013204. https:\/\/doi.org\/10.1097\/SLA.0b013e31826f4b0e","journal-title":"Ann Surg"},{"issue":"6","key":"9_CR25","doi-asserted-by":"publisher","first-page":"791","DOI":"10.5009\/gnl14243","volume":"9","author":"KM Kim","year":"2015","unstructured":"Kim KM, Park JW, Lee JK, Lee KH, Lee KT, Shim SG (2015) A comparison of preoperative biliary drainage methods for perihilar cholangiocarcinoma: endoscopic versus percutaneous transhepatic biliary drainage. Gut Liver. 9(6):791\u2013799. https:\/\/doi.org\/10.5009\/gnl14243","journal-title":"Gut Liver."},{"issue":"2","key":"9_CR26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s005340050164","volume":"7","author":"KD Lillemoe","year":"2000","unstructured":"Lillemoe KD, Cameron JL (2000) Surgery for hilar cholangiocarcinoma: the Johns Hopkins approach. J Hepatobiliary Pancreat Surg 7(2):115\u2013121. https:\/\/doi.org\/10.1007\/s005340050164","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"9_CR27","doi-asserted-by":"publisher","unstructured":"Coelen RJS, Roos E, Wiggers JK et al (2018) Endoscopic versus percutaneous biliary drainage in patients with resectable perihilar cholangiocarcinoma: a multicentre, randomised controlled trial. Lancet Gastroenterol Hepatol 3(10):681\u2013690. https:\/\/doi.org\/10.1016\/S2468-1253(18)30234-6","DOI":"10.1016\/S2468-1253(18)30234-6"},{"issue":"4","key":"9_CR28","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1097\/01.sla.0000118594.23874.89","volume":"239","author":"S Kamiya","year":"2004","unstructured":"Kamiya S, Nagino M, Kanazawa H et al (2004) The value of bile replacement during external biliary drainage: an analysis of intestinal permeability, integrity, and microflora. Ann Surg 239(4):510\u2013517. https:\/\/doi.org\/10.1097\/01.sla.0000118594.23874.89","journal-title":"Ann Surg"},{"issue":"11","key":"9_CR29","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/bjs.8906","volume":"99","author":"R Otao","year":"2012","unstructured":"Otao R, Beppu T, Isiko T et al (2012) External biliary drainage and liver regeneration after major hepatectomy. Br J Surg 99(11):1569\u20131574. https:\/\/doi.org\/10.1002\/bjs.8906","journal-title":"Br J Surg"},{"issue":"5","key":"9_CR30","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1002\/hep.1840200532","volume":"20","author":"H Suzuki","year":"1994","unstructured":"Suzuki H, Iyomasa S, Nimura Y, Yoshida S (1994) Internal biliary drainage, unlike external drainage, does not suppress the regeneration of cholestatic rat liver after partial hepatectomy. Hepatology 20(5):1318\u20131322","journal-title":"Hepatology"},{"issue":"5","key":"9_CR31","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s12072-016-9723-8","volume":"10","author":"LF van de Laarschot","year":"2016","unstructured":"van de Laarschot LF, Jansen PL, Schaap FG, Olde Damink SW (2016) The role of bile salts in liver regeneration. Hepatol Int 10(5):733\u2013740. https:\/\/doi.org\/10.1007\/s12072-016-9723-8","journal-title":"Hepatol Int"},{"issue":"12","key":"9_CR32","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1007\/s11605-014-2674-2","volume":"18","author":"Y Yoshida","year":"2014","unstructured":"Yoshida Y, Ajiki T, Ueno K et al (2014) Preoperative bile replacement improves immune function for jaundiced patients treated with external biliary drainage. J Gastrointest Surg 18(12):2095\u20132104. https:\/\/doi.org\/10.1007\/s11605-014-2674-2","journal-title":"J Gastrointest Surg"},{"issue":"2","key":"9_CR33","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/jso.24633","volume":"116","author":"BN Reames","year":"2017","unstructured":"Reames BN, Ejaz A, Koerkamp BG et al (2017) Impact of major vascular resection on outcomes and survival in patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis. J Surg Oncol 116(2):133\u2013139. https:\/\/doi.org\/10.1002\/jso.24633","journal-title":"J Surg Oncol"},{"issue":"2","key":"9_CR34","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1177\/0003134820951451","volume":"87","author":"M Dixon","year":"2021","unstructured":"Dixon M, Cruz J, Sarwani N, Gusani N (2021) The future liver remnant: definition, evaluation, and management. Am Surg 87(2):276\u2013286. https:\/\/doi.org\/10.1177\/0003134820951451","journal-title":"Am Surg"},{"issue":"6","key":"9_CR35","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1245\/s10434-017-5800-z","volume":"24","author":"S Yamashita","year":"2017","unstructured":"Yamashita S, Sakamoto Y, Yamamoto S et al (2017) Efficacy of preoperative portal vein embolization among patients with hepatocellular carcinoma, biliary tract cancer, and colorectal liver metastases: a comparative study based on single-center experience of 319 cases. Ann Surg Oncol 24(6):1557\u20131568. https:\/\/doi.org\/10.1245\/s10434-017-5800-z","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"9_CR36","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1159\/000335718","volume":"29","author":"T Ebata","year":"2012","unstructured":"Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, Nagino M (2012) Portal vein embolization before extended hepatectomy for biliary cancer: current technique and review of 494 consecutive embolizations. Dig Surg 29(1):23\u201329. https:\/\/doi.org\/10.1159\/000335718","journal-title":"Dig Surg"},{"issue":"4","key":"9_CR37","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.soc.2019.06.010","volume":"28","author":"TC Lee","year":"2019","unstructured":"Lee TC, Morris MC, Patel SH, Shah SA (2019) Expanding the surgical pool for hepatic resection to treat biliary and primary liver tumors. Surg Oncol Clin N Am 28(4):763\u2013782. https:\/\/doi.org\/10.1016\/j.soc.2019.06.010","journal-title":"Surg Oncol Clin N Am"},{"issue":"4","key":"9_CR38","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/s1072-7515(01)01016-x","volume":"193","author":"SM Weber","year":"2001","unstructured":"Weber SM, Jarnagin WR, Klimstra D, DeMatteo RP, Fong Y, Blumgart LH (2001) Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg 193(4):384\u2013391. https:\/\/doi.org\/10.1016\/s1072-7515(01)01016-x","journal-title":"J Am Coll Surg"},{"key":"9_CR39","doi-asserted-by":"publisher","unstructured":"Khan SA, Davidson BR, Goldin R et al (2002) Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 51(Suppl 6):Vi1\u2013Vi9. https:\/\/doi.org\/10.1136\/gut.51.suppl_6.vi1","DOI":"10.1136\/gut.51.suppl_6.vi1"},{"issue":"3","key":"9_CR40","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1080\/13651820801992542","volume":"10","author":"CB Rosen","year":"2008","unstructured":"Rosen CB, Heimbach JK, Gores GJ (2008) Surgery for cholangiocarcinoma: the role of liver transplantation. HPB 10(3):186\u2013189. https:\/\/doi.org\/10.1080\/13651820801992542","journal-title":"HPB"},{"issue":"8","key":"9_CR41","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1200\/jco.18.00050","volume":"37","author":"J Edeline","year":"2019","unstructured":"Edeline J, Benabdelghani M, Bertaut A et al (2019) Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol 37(8):658\u2013667. https:\/\/doi.org\/10.1200\/jco.18.00050","journal-title":"J Clin Oncol"},{"issue":"5","key":"9_CR42","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/s1470-2045(18)30915-x","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose JN, Fox RP, Palmer DH et al (2019) Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 20(5):663\u2013673. https:\/\/doi.org\/10.1016\/s1470-2045(18)30915-x","journal-title":"Lancet Oncol"},{"key":"9_CR43","doi-asserted-by":"publisher","unstructured":"Stein A, Arnold D, Bridgewater J et al (2015) Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial)\u2014a randomized, multidisciplinary, multinational phase III trial. BMC Cancer 15:564. https:\/\/doi.org\/10.1186\/s12885-015-1498-0","DOI":"10.1186\/s12885-015-1498-0"},{"issue":"11","key":"9_CR44","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/s2468-1253(21)00171-0","volume":"6","author":"AE Kam","year":"2021","unstructured":"Kam AE, Masood A, Shroff RT (2021) Current and emerging therapies for advanced biliary tract cancers. Lancet Gastroenterol Hepatol 6(11):956\u2013969. https:\/\/doi.org\/10.1016\/s2468-1253(21)00171-0","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"9_CR45","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1093\/annonc\/mdh351","volume":"15","author":"T Andr\u00e9","year":"2004","unstructured":"Andr\u00e9 T, Tournigand C, Rosmorduc O et al (2004) Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 15(9):1339\u20131343. https:\/\/doi.org\/10.1093\/annonc\/mdh351","journal-title":"Ann Oncol"},{"issue":"5","key":"9_CR46","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1093\/annonc\/mdz058","volume":"30","author":"ST Kim","year":"2019","unstructured":"Kim ST, Kang JH, Lee J et al (2019) Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial. Ann Oncol 30(5):788\u2013795. https:\/\/doi.org\/10.1093\/annonc\/mdz058","journal-title":"Ann Oncol"},{"issue":"30","key":"9_CR47","doi-asserted-by":"publisher","first-page":"4581","DOI":"10.1200\/jco.2010.29.3605","volume":"28","author":"A Sharma","year":"2010","unstructured":"Sharma A, Dwary AD, Mohanti BK et al (2010) Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol 28(30):4581\u20134586. https:\/\/doi.org\/10.1200\/jco.2010.29.3605","journal-title":"J Clin Oncol"},{"key":"9_CR48","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ejca.2019.10.004","volume":"123","author":"A Sharma","year":"2019","unstructured":"Sharma A, Kalyan Mohanti B, Pal Chaudhary S et al (2019) Modified gemcitabine and oxaliplatin or gemcitabine + cisplatin in unresectable gallbladder cancer: Results of a phase III randomised controlled trial. Eur J Cancer 123:162\u2013170. https:\/\/doi.org\/10.1016\/j.ejca.2019.10.004","journal-title":"Eur J Cancer"},{"issue":"9","key":"9_CR49","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1158\/2159-8290.Cd-17-0245","volume":"7","author":"JW Valle","year":"2017","unstructured":"Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX (2017) New horizons for precision medicine in biliary tract cancers. Cancer Discov 7(9):943\u2013962. https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-0245","journal-title":"Cancer Discov"},{"issue":"4","key":"9_CR50","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.soc.2019.06.015","volume":"28","author":"S Sadeghi","year":"2019","unstructured":"Sadeghi S, Bejjani A, Finn RS (2019) Systemic therapy for primary liver tumors: cholangiocarcinoma and hepatocellular carcinoma. Surg Oncol Clin N Am 28(4):695\u2013715. https:\/\/doi.org\/10.1016\/j.soc.2019.06.015","journal-title":"Surg Oncol Clin N Am"},{"issue":"3","key":"9_CR51","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1200\/jco.2017.75.5009","volume":"36","author":"M Javle","year":"2018","unstructured":"Javle M, Lowery M, Shroff RT et al (2018) Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol 36(3):276\u2013282. https:\/\/doi.org\/10.1200\/jco.2017.75.5009","journal-title":"J Clin Oncol"},{"issue":"5","key":"9_CR52","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/s1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A et al (2020) Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 21(5):671\u2013684. https:\/\/doi.org\/10.1016\/s1470-2045(20)30109-1","journal-title":"Lancet Oncol"},{"issue":"15","key":"9_CR53","doi-asserted-by":"publisher","first-page":"24644","DOI":"10.18632\/oncotarget.15602","volume":"8","author":"J Fontugne","year":"2017","unstructured":"Fontugne J, Augustin J, Pujals A et al (2017) PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma. Oncotarget 8(15):24644\u201324651. https:\/\/doi.org\/10.18632\/oncotarget.15602","journal-title":"Oncotarget"},{"issue":"22","key":"9_CR54","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378(22):2078\u20132092. https:\/\/doi.org\/10.1056\/NEJMoa1801005","journal-title":"N Engl J Med"},{"issue":"26","key":"9_CR55","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517\u20132526. https:\/\/doi.org\/10.1056\/NEJMoa1104621","journal-title":"N Engl J Med"},{"key":"9_CR56","doi-asserted-by":"publisher","unstructured":"Oh D-Y, He AR, Qin S et al (2022) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 1(8):EVIDoa2200015. https:\/\/doi.org\/10.1056\/EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015"},{"issue":"9319","key":"9_CR57","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/s0140-6736(02)08649-x","volume":"359","author":"JM Llovet","year":"2002","unstructured":"Llovet JM, Real MI, Monta\u00f1a X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359(9319):1734\u20131739. https:\/\/doi.org\/10.1016\/s0140-6736(02)08649-x","journal-title":"Lancet"},{"issue":"5","key":"9_CR58","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","volume":"35","author":"CM Lo","year":"2002","unstructured":"Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35(5):1164\u20131171. https:\/\/doi.org\/10.1053\/jhep.2002.33156","journal-title":"Hepatology"},{"issue":"12","key":"9_CR59","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.1245\/s10434-013-3127-y","volume":"20","author":"O Hyder","year":"2013","unstructured":"Hyder O, Marsh JW, Salem R et al (2013) Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann Surg Oncol 20(12):3779\u20133786. https:\/\/doi.org\/10.1245\/s10434-013-3127-y","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"9_CR60","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/01.Rvi.0000143768.60751.78","volume":"16","author":"I Burger","year":"2005","unstructured":"Burger I, Hong K, Schulick R et al (2005) Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol 16(3):353\u2013361. https:\/\/doi.org\/10.1097\/01.Rvi.0000143768.60751.78","journal-title":"J Vasc Interv Radiol"},{"key":"9_CR61","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/BF02165860","volume":"19","author":"B Choi","year":"1994","unstructured":"Choi B, Han J, Kim Y et al (1994) Combined hepatocellular and cholangiocarcinoma of the liver: sonography, CT, angiography, and iodized-oil CT with pathologic correlation. Abdom Imaging 19:43\u201346","journal-title":"Abdom Imaging"},{"issue":"1","key":"9_CR62","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1148\/118.1.19","volume":"118","author":"JF Walter","year":"1976","unstructured":"Walter JF, Bookstein JJ, Bouffard EV (1976) Newer angiographic observations in cholangiocarcinoma. Radiology 118(1):19\u201323","journal-title":"Radiology"},{"key":"9_CR63","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.1245\/s10434-013-3127-y","volume":"20","author":"O Hyder","year":"2013","unstructured":"Hyder O, Marsh JW, Salem R et al (2013) Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann Surg Oncol 20:3779\u20133786","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"9_CR64","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/jamaoncol.2019.3702","volume":"6","author":"J Edeline","year":"2020","unstructured":"Edeline J, Touchefeu Y, Guiu B et al (2020) Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol 6(1):51\u201359","journal-title":"JAMA Oncol"},{"issue":"9","key":"9_CR65","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1093\/annonc\/mdp029","volume":"20","author":"WR Jarnagin","year":"2009","unstructured":"Jarnagin WR, Schwartz LH, Gultekin DH et al (2009) Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol 20(9):1589\u20131595. https:\/\/doi.org\/10.1093\/annonc\/mdp029","journal-title":"Ann Oncol"},{"issue":"7","key":"9_CR66","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1002\/cncr.20964","volume":"103","author":"M Cantore","year":"2005","unstructured":"Cantore M, Mambrini A, Fiorentini G et al (2005) Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors. Cancer 103(7):1402\u20131407. https:\/\/doi.org\/10.1002\/cncr.20964","journal-title":"Cancer"},{"issue":"4c","key":"9_CR67","first-page":"3009","volume":"27","author":"A Mambrini","year":"2007","unstructured":"Mambrini A, Guglielmi A, Pacetti P et al (2007) Capecitabine plus hepatic intra-arterial epirubicin and cisplatin in unresectable biliary cancer: a phase II study. Anticancer Res 27(4c):3009\u20133013","journal-title":"Anticancer Res"},{"issue":"8","key":"9_CR68","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1007\/s10620-013-2624-y","volume":"58","author":"M Sinn","year":"2013","unstructured":"Sinn M, Nicolaou A, Gebauer B et al (2013) Hepatic arterial infusion with oxaliplatin and 5-FU\/folinic acid for advanced biliary tract cancer: a phase II study. Dig Dis Sci 58(8):2399\u20132405. https:\/\/doi.org\/10.1007\/s10620-013-2624-y","journal-title":"Dig Dis Sci"}],"container-title":["Cancer Treatment and Research","Gastrointestinal Malignancies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-61238-1_9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T02:05:28Z","timestamp":1724983528000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-61238-1_9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9783031612374","9783031612381"],"references-count":68,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-61238-1_9","relation":{},"ISSN":["0927-3042","2509-8497"],"issn-type":[{"value":"0927-3042","type":"print"},{"value":"2509-8497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"31 August 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}